Avastin, in combination with intravenous 5-FU–based chemotherapy, is approved by the FDA for first- or second-line treatment of people with metastatic cancer of the colon or rectum.
Avastin, in combination with carboplatin and paclitaxel (chemotherapy), is approved by the FDA for first-line treatment of people newly diagnosed with a common form of NSCLC (unresectable, locally advanced, recurrent, or metastatic non-squamous, non-small cell lung cancer).
Avastin in combination with paclitaxel, a type of chemotherapy, is approved for treating patients with HER2-negative metastatic breast cancer (MBC) who have not yet received chemotherapy for their advanced disease. The effectiveness of Avastin in HER2-negative MBC is based on an improvement in how long your tumor remains controlled. Currently, there are no data available showing that Avastin improves disease-related symptoms or survival in HER2-negative MBC. Avastin is not approved for people who have received prior anthracycline and taxane (chemotherapy) for their HER2-negative MBC.
Avastin is approved by the FDA for use on its own for treating glioblastoma (GBM) that has progressed after prior treatment. The effectiveness of Avastin in GBM is based on tumor response. Currently, no data have shown whether Avastin improves disease-related symptoms or survival in people previously treated for GBM.
Avastin, in combination with interferon alfa, is approved by the FDA for the treatment of metastatic kidney cancer.
What is the most important safety information I should know about Avastin?
Avastin can result in the development of a potentially serious, and sometimes fatal, side effect called gastrointestinal (GI) perforation. GI perforation is the development of a hole in the stomach, small intestine, or large intestine. Symptoms may include abdominal pain, nausea, vomiting, constipation, and fever. Avastin therapy should be stopped if GI perforation occurs.
Treatment with Avastin can lead to slow or incomplete wound healing (for example, when a surgical incision has trouble healing or staying closed). In some cases, this event resulted in fatality. Stop Avastin for at least 28 days before voluntary surgery. Do not start Avastin for at least 28 days after surgery and until the surgical wound is fully healed. Avastin therapy should be stopped in patients who experience slow or incomplete wound healing.
Treatment with Avastin can result in serious and sometimes fatal bleeding. This includes coughing up blood, bleeding in the stomach, vomiting blood, bleeding in the brain, nosebleeds, and vaginal bleeding. People who have recently coughed up blood or have serious bleeding should not receive Avastin.
What are the additional possible serious side effects of Avastin?
Serious side effects with Avastin include:
What are the most common side effects of Avastin?
The most common side effects of Avastin that occurred at >10% and at least twice the control rate include nosebleeds, headache, high blood pressure, inflammation of the nose, too much protein in the urine, taste change, dry skin, rectal bleeding, tear production disorder, back pain, and inflammation of the skin.
What should I do if I am pregnant or thinking of becoming pregnant?
You should not take Avastin while you are pregnant. If you stop Avastin, you should use a contraceptive for at least 6 months after your last dose before attempting to become pregnant.
What should I tell my health care provider before taking Avastin?
Avastin therapy may not be appropriate for certain people. Talk to your doctor if you:
Please see full Product Information, including Serious Side Effects, for additional important safety information.